published_or_final_version / Community Medicine / Master / Master of Public Health

Ng, Chun Fai. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2013. / Includes bibliographical references (leaves 176-197). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

Siu Yuen-man. / Thesis submitted in: September 2003. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 249-251). / Abstracts in English and Chinese. / Abstract --- p.i / Acknowledgments --- p.iii / Note on the Transliteration --- p.vii / Chapter 1. --- Introduction --- p.1 / Chapter 2. --- The General Public View on Health Consciousness and Qigong --- p.49 / Chapter 3. --- The Life Stories of the Informants --- p.64 / Chapter 4. --- The Perception of the Informants on Diseases --- p.96 / Chapter 5. --- "The Attitudes of the Informants towards Biomedicine, Traditional Chinese Medicine, and Qigong" --- p.123 / Chapter 6. --- The Motivations of the Qigong Followers for Practicing Qigong --- p.165 / Chapter 7. --- Conclusion --- p.212 / Appendix1 --- p.238 / Appendix2 --- p.240 / Appendix3 --- p.242 / Appendix4 --- p.246 / Bibliography --- p.249

Cao Hui. / Publication date from spine. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1995. / Includes bibliographical references (leaves 180-194). / Acknowledgments --- p.v / Abstract --- p.vii / List of Tables --- p.xv / List of Figures --- p.xvii / Abbreviations and symbols --- p.xx / Chapter Chapter 1. --- General introduction / Chapter 1.1. --- Historical background --- p.1 / Chapter 1.2. --- Pharmacognostical development --- p.2 / Chapter 1.3. --- Importance of herb authentication --- p.3 / Chapter 1.4. --- Objective of study --- p.5 / Chapter Chapter 2. --- Literature review / Chapter 2.1. --- Botanical and taxonomic aspects --- p.9 / Chapter 2.1.1. --- Morphology --- p.9 / Chapter 2.1.2. --- Scientific names --- p.11 / Chapter 2.2. --- Chemical aspects --- p.13 / Chapter 2.3. --- Pharmacological aspects --- p.14 / Chapter 2.3.1. --- Antibacterial effect --- p.14 / Chapter 2.3.2. --- Antiphlogistic effect --- p.14 / Chapter 2.3.3. --- Antipyretic effect --- p.15 / Chapter 2.3.4. --- Effect in gastrointestinal propulsion --- p.15 / Chapter 2.3.5. --- Antineoplastic activity --- p.15 / Chapter 2.3.6. --- Hepatoprotective effect --- p.15 / Chapter 2.3.7. --- Inhibitory activity on enzymes --- p.17 / Chapter 2.3.8. --- Cardiovascular effect --- p.17 / Chapter 2.3.9. --- Acute toxicity (LD50) --- p.18 / Chapter 2.4. --- Pharmacognostical aspects --- p.18 / Chapter Chapter 3. --- Kudidan in Ben-cao literature / Chapter 3.1. --- Introduction --- p.23 / Chapter 3.2. --- Name evolution --- p.23 / Chapter 3.3. --- Natural distribution --- p.24 / Chapter 3.4. --- Characteristics --- p.25 / Chapter 3.5. --- Substitutions investigation --- p.26 / Chapter 3.6. --- Summary --- p.29 / Chapter Chapter 4. --- Morphological differences / Chapter 4.1. --- Plant identification --- p.36 / Chapter 4.1.1. --- Introduction --- p.36 / Chapter 4.1.2. --- Collection of voucher materials --- p.36 / Chapter 4.1.3. --- Plant morphology --- p.36 / Chapter 4.2. --- Macroscopical identification --- p.46 / Chapter 4.2.1. --- Introduction --- p.46 / Chapter 4.2.2. --- Materials and methods --- p.46 / Chapter 4.2.2.1. --- Commercial samples --- p.46 / Chapter 4.2.2.2. --- Macroscopical characteristics --- p.46 / Chapter 4.2.3. --- Results --- p.49 / Chapter Chapter 5. --- Histological identification / Chapter 5.1. --- Introduction --- p.58 / Chapter 5.2. --- Materials and methods --- p.59 / Chapter 5.2.1. --- Commercial samples --- p.59 / Chapter 5.2.1.1. --- Kudidan --- p.59 / Chapter 5.2.1.2. --- Pugongying --- p.59 / Chapter 5.2.1.3. --- Substitutes --- p.59 / Chapter 5.2.2. --- Authentic plant materials for comparison --- p.60 / Chapter 5.2.3. --- Methods --- p.60 / Chapter 5.2.3.1. --- Paraffin method --- p.60 / Chapter 5.2.3.2. --- Light microscopy --- p.62 / Chapter 5.2.3.3. --- Quantitative microscopy --- p.63 / Chapter 5.2.3.4. --- Scanning electron microscopy --- p.64 / Chapter 5.3. --- Results --- p.64 / Chapter 5.3.1. --- Microscopical characters of comparative plants --- p.64 / Chapter 5.3.2. --- Internal structures of herbs --- p.83 / Chapter 5.4. --- Discussion --- p.83 / Chapter Chapter 6. --- Chemical analysis / Chapter 6.1. --- Introduction --- p.99 / Chapter 6.2. --- Materials and methods --- p.100 / Chapter 6.2.1. --- Authentic samples --- p.100 / Chapter 6.2.2. --- Commercial samples --- p.100 / Chapter 6.2.3. --- Methods --- p.100 / Chapter 6.2.3.1. --- Isolation and characterization of standard substances --- p.100 / Chapter 6.2.3.2. --- Extraction of plant materials --- p.102 / Chapter 6.2.3.3. --- Thin layer chromatography --- p.102 / Chapter 6.3. --- Results and discussion --- p.104 / Chapter 6.3.1. --- TLC synopsis --- p.104 / Chapter 6.3.2. --- TLC analysis --- p.105 / Chapter 6.3.2.1. --- Qualitative evaluation of authentic plants --- p.105 / Chapter 6.3.2.2. --- Qualitative evaluation of commercial samples --- p.107 / Chapter 6.4. --- Summary --- p.107 / Chapter Chapter 7. --- Molecular fingerprinting / Chapter 7.1. --- Introduction --- p.115 / Chapter 7.2. --- Materials and methods --- p.120 / Chapter 7.2.1. --- Plant materials --- p.121 / Chapter 7.2.2. --- Herbal materials --- p.121 / Chapter 7.2.3. --- Total genomic DNA preparation --- p.121 / Chapter 7.2.3.1. --- CsCl/EtBr gradient method --- p.121 / Chapter 7.2.3.2. --- CTAB/CsCl gradient method --- p.123 / Chapter 7.2.3.3. --- CTAB miniprep method --- p.124 / Chapter 7.2.4. --- Qualitative analysis of genomic DNA --- p.125 / Chapter 7.2.5. --- Quantitative analysis of genomic DNA --- p.126 / Chapter 7.2.6. --- Genomic DNA fingerprinting --- p.126 / Chapter 7.2.6.1. --- DNA amplification --- p.126 / Chapter 7.2.6.1.1. --- AP-PCR --- p.127 / Chapter 7.2.1.1.2. --- RAPD --- p.128 / Chapter 7.2.6.2. --- Data analysis --- p.129 / Chapter 7.3. --- Results --- p.129 / Chapter 7.3.1. --- Studies on extraction of genomic DNA --- p.129 / Chapter 7.3.2. --- Genomic DNA fingerprinting by AP-PCR --- p.130 / Chapter 7.3.3. --- Genomic DNA fingerprinting by RAPD --- p.131 / Chapter 7.4. --- Discussion --- p.131 / Chapter 7.4.1. --- DNA extraction --- p.132 / Chapter 7.4.2. --- DNA fingerprinting of Kudidan --- p.136 / Chapter 7.4.3. --- Phylogenetic relationship between two genera Elephantopus and Pseudo-elephantopus of by DNA fingerprinting --- p.141 / Chapter Chapter 8. --- General summary and conclusion / Chapter 8.1. --- General summary --- p.165 / Chapter 8.1.1. --- Ben-cao investigation --- p.166 / Chapter 8.1.2. --- Investigation of commercial samples --- p.166 / Chapter 8.1.3. --- Histological characteristics --- p.167 / Chapter 8.1.4. --- Chemical analysis --- p.168 / Chapter 8.1.5. --- DNA fingerprinting --- p.168 / Chapter 8.2. --- Conclusion --- p.169 / Appendices / Chapter A) --- Solutions --- p.171 / Chapter B) --- Chinese characters cited in this Thesis --- p.173 / Chapter a) --- Herbal names --- p.173 / Chapter b) --- Book names --- p.175 / Chapter c) --- Personal names --- p.176 / Chapter d) --- Place names --- p.177 / Chapter e) --- Miscellaneous names --- p.179 / Bibliography --- p.180

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

published_or_final_version / Medicine / Doctoral / Doctor of Philosophy

Wang, Xiaoan. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 145-166). / Abstracts in English and Chinese. / Table of Contents --- p.I / Acknowledgements --- p.VI / Publications --- p.VII / Abstract (in English) --- p.VIII / Abstract (in Chinese) --- p.X / List of Figures --- p.XII / List of Tables --- p.XVI / List of Abbreviations --- p.XVII / Chapter Chapter One. --- Introduction --- p.1 / Chapter 1.1 --- Overview of oseltamivir --- p.1 / Chapter 1.1.1 --- General description of oseltamivir --- p.1 / Chapter 1.1.2 --- Pharmacological activities of oseltamivir --- p.3 / Chapter 1.1.3 --- Pharmacokinetics of oseltamivir --- p.3 / Chapter 1.1.3.1 --- Absorption of oseltamivir --- p.4 / Chapter 1.1.3.2 --- Distribution of oseltamivir --- p.5 / Chapter 1.1.3.3 --- Metabolism of oseltamivir --- p.6 / Chapter 1.1.3.4 --- Elimination of oseltamivir --- p.8 / Chapter 1.1.4 --- Side effects and toxicities of oseltamivir --- p.9 / Chapter 1.2 --- Overview of Chinese medicine formulae CMF1 (Yinqiaosan and Sangjuyin) --- p.9 / Chapter 1.2.1 --- Background and clinical use of CMF1 --- p.9 / Chapter 1.2.2 --- Quality control of CMF1 by manufacturer --- p.11 / Chapter 1.2.3 --- Major active components of CMF1 --- p.12 / Chapter 1.3 --- Previous studies on herb-drug interactions between O and CMF1 --- p.18 / Chapter 1.4 --- Rationale of the current study --- p.19 / Chapter 1.5 --- objectives --- p.19 / Chapter Chapter Two. --- Identification and quantification of major marker compounds in Yinqiaosan and Sangiuyin products --- p.20 / Chapter 2.1 --- Introduction --- p.20 / Chapter 2.2 --- Materials and methods --- p.23 / Chapter 2.2.1 --- Chemicals --- p.23 / Chapter 2.2.2 --- Instruments --- p.24 / Chapter 2.2.3 --- Chromatographic conditions --- p.24 / Chapter 2.2.4 --- Preparation of standard solutions --- p.25 / Chapter 2.2.5 --- Calibration curves --- p.26 / Chapter 2.2.6 --- Validation of the assay method --- p.26 / Chapter 2.2.7 --- Sample preparations for Yinqiaosan and Sangjuyin products --- p.27 / Chapter 2.2.7.1 --- Sample extraction from Yinqiaosan or Sangjuyin granules --- p.27 / Chapter 2.2.7.2 --- Sample extraction from Yinqiaosan or Sangjuyin tablets --- p.27 / Chapter 2.2.7.3 --- Sample extraction recoveries --- p.27 / Chapter 2.3 --- Results and discussions --- p.28 / Chapter 2.3.1 --- Chromatography --- p.28 / Chapter 2.3.2 --- Linearity and sensitivity --- p.33 / Chapter 2.3.3 --- Accuracy and precision --- p.33 / Chapter 2.3.4 --- Stability --- p.36 / Chapter 2.3.5 --- Contents of identified active components in commercial available Yinqiaosan or Sangjuyin products and CMF1 --- p.36 / Chapter 2.3.6 --- Sample extraction recovery --- p.40 / Chapter 2.4 --- Conclusion --- p.43 / Chapter Chapter Three. --- Effect of CMF1/CMF1 components on the metabolism of oseltamivir and related mechanistic studies --- p.44 / Chapter 3.1 --- Introduction --- p.44 / Chapter 3.2 --- Materials and methods --- p.47 / Chapter 3.2.1 --- Materials --- p.47 / Chapter 3.2.2 --- "Verification of metabolism of O in rat GI tract, plasma and liver microsome" --- p.48 / Chapter 3.2.3 --- Inhibition of metabolism of O by CMFl/CMFl components --- p.49 / Chapter 3.2.3.1 --- In vitro inhibition of metabolism of O in rat plasma --- p.49 / Chapter 3.2.3.2 --- In vitro inhibition of metabolism of O in rat liver microsome (RLM) --- p.49 / Chapter 3.2.4 --- Mechanistic study of enzyme inhibition of O in recombinant human Carboxylesterase 1 (hCE 1) --- p.50 / Chapter 3.2.5 --- Sample preparation and LC/MS/MS analysis --- p.50 / Chapter 3.2.6 --- Data analyses --- p.52 / Chapter 3.3 --- Results --- p.53 / Chapter 3.3.1 --- "Verification of metabolism of O in rat GI tract, plasma and liver microsome" --- p.53 / Chapter 3.3.2 --- Inhibition of metabolism of O by CMF1/CMF1 components --- p.53 / Chapter 3.3.2.1 --- Enzyme inhibition of metabolism of O by CMFl/CMF1 components in rat plasma --- p.53 / Chapter 3.3.2.2 --- Enzyme inhibition of metabolism of O by CMF1/CMF1 components in rat liver microsome (RLM) --- p.58 / Chapter 3.3.2.3 --- Selection of potent enzyme inhibitor from CMF1 --- p.60 / Chapter 3.3.4. --- Mechanistic study of enzyme inhibition of O in recombinant human Carboxylesterase 1 (hCE 1) --- p.61 / Chapter 3.4 --- Discussions --- p.63 / Chapter 3.5 --- Conclusion --- p.74 / Chapter Chapter Four. --- Effect of CMFl/CMFl components on the absorption of oseltamivir and related mechanistic studies --- p.75 / Chapter 4.1 --- Introduction --- p.75 / Chapter 4.2 --- Materials and methods --- p.79 / Chapter 4.2.1 --- Materials --- p.79 / Chapter 4.2.2 --- PAMPA permeation model --- p.80 / Chapter 4.2.2.1 --- Permeation of O and OC in PAMPA --- p.80 / Chapter 4.2.2.2 --- Sample preparation and LC/MS/MS analysis --- p.81 / Chapter 4.2.2.3 --- Data analysis --- p.81 / Chapter 4.2.3 --- Absorption of O in presence of CMF/CMFl components in Caco-2 and MDCK cell monolayer models --- p.82 / Chapter 4.2.3.1 --- Cell culture --- p.82 / Chapter 4.2.3.2 --- Preparation of loading solutions to the cell models --- p.83 / Chapter 4.2.3.3 --- Stability of O in transport buffer --- p.84 / Chapter 4.2.3.4 --- Cytotoxicity tests of O and CMFl/CMFl components --- p.84 / Chapter 4.2.3.5 --- Transport study in Caco-2 and MDCK monolayer model --- p.85 / Chapter 4.2.3.6 --- Sample preparation and LC/MS/MS analysis --- p.86 / Chapter 4.2.3.7 --- Data analysis --- p.87 / Chapter 4.2.4 --- Absorption of O in presence of CMF 1 in rat in situ single pass intestinal perfusion model --- p.88 / Chapter 4.2.4.1 --- Preparation of perfusion solutions --- p.88 / Chapter 4.2.4.2 --- Stabilities of O and arctigenin in perfusate --- p.88 / Chapter 4.2.4.3 --- Rat in situ single pass intestinal perfusion of O in presence and absence of CMFl and relevant inhibitors --- p.89 / Chapter 4.2.4.4 --- Sample preparation and LC/MS/MS analysis --- p.90 / Chapter 4.2.4.5 --- Data analysis --- p.90 / Chapter 4.3 --- Resul ts --- p.91 / Chapter 4.3.1 --- Permeation of O and OC in PAMPA --- p.91 / Chapter 4.3.2 --- Absorption of O in presence of CMF/CMF1 components in Caco-2 and MDCK cell monolayer models --- p.92 / Chapter 4.3.2.1 --- Stabilities of O in transport buffer --- p.92 / Chapter 4.3.2.2 --- Cytotoxicity tests of O and CMF1/CMF1 components in transport buffer --- p.93 / Chapter 4.3.2.3 --- Proof of O as a substrate of P-gp by Caco-2 cell model --- p.95 / Chapter 4.3.2.4 --- Effect of CMF 1 on the absorption transport of o in Caco-2 cell mode --- p.98 / Chapter 4.3.2.5 --- Effect of CMF1 components on the absorption transport of o in Caco-2 cell model --- p.102 / Chapter 4.3.2.6 --- Effect of arctigenin on bi-directional transport of o in Caco- 2 cell model --- p.106 / Chapter 4.3.2.7 --- Proof of O as a substrate of P-gp by MDCK transfected cell lines --- p.108 / Chapter 4.3.2.8 --- Bi-directional transport of O in MDCK-MDR1 cell model --- p.111 / Chapter 4.3.2.9 --- Effect of CMF 1 on the absorption transport of O in MDCK-MDR1 cell model --- p.112 / Chapter 4.3.3 --- Absorption of O in presence of CMF1 in rat in situ single pass intestinal perfusion model --- p.113 / Chapter 4.3.3.1 --- Stabilities of O and arctigenin in the perfusion buffer --- p.113 / Chapter 4.3.3.2 --- Intestinal absorption of O in presence and absence of CMF1 in rat in situ intestinal perfusion model --- p.114 / Chapter 4.4 --- Discussions --- p.116 / Chapter 4.5 --- Conclusion --- p.124 / Chapter Chapter Five. --- Preliminary evaluation of antiviral activity of CMFl/CMFl components --- p.125 / Chapter 5.1 --- Introduction --- p.125 / Chapter 5.2 --- Materials and methods --- p.128 / Chapter 5.2.1 --- Materials and animals --- p.128 / Chapter 5.2.2 --- Animal treatment --- p.129 / Chapter 5.2.3 --- Plasma sample collection and preparation --- p.130 / Chapter 5.2.4 --- Evaluation of antiviral activities of CMFl/ CMFl components --- p.130 / Chapter 5.2.4.1 --- Plaque reduction assay --- p.131 / Chapter 5.2.4.2 --- Optimization of plasma sample dilution ratio --- p.131 / Chapter 5.2.5 --- Data analyses --- p.133 / Chapter 5.3 --- Results and discussions --- p.135 / Chapter 5.3.1 --- Ex vivo evaluation of antiviral activity of CMF1 --- p.135 / Chapter 5.3.2 --- In vitro evaluation of antiviral activity of CMF1 major marker compounds --- p.139 / Chapter 5.4 --- Conclusion --- p.141 / Chapter Chapter Six. --- Overall conclusion --- p.142 / References --- p.145

by Cheng Yuk Kwan, Anna. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1993. / Includes bibliographical references (leaves 104-112). / Acknowledgements / Table of Contents --- p.i / Abbreviations --- p.iv / Abstract --- p.vi / List of figures --- p.ix / List of tables --- p.xi / Chapter Chapter One: --- Introduction / Chapter 1.1 --- Objective and scope of the project --- p.1 / Chapter 1.2 --- Literature review of Mimosa pudica / Chapter 1.2.1 --- Morphology of Mimosa pudica --- p.3 / Chapter 1.2.2 --- Chemistry of Mimosa pudica --- p.5 / Chapter 1.2.3 --- Uses in traditional medicine --- p.5 / Chapter 1.2.4 --- Clinical and pharmacological studies of Mimosa pudica --- p.6 / Chapter 1.2.5 --- Toxicology of Mimosa pudica --- p.8 / Chapter 1.2.6 --- Characteristics and toxicology of mimosine --- p.9 / Chapter 1.3 --- Immunomodulation / Chapter 1.3.1 --- Overview of the immune system --- p.11 / Chapter 1.3.2 --- Strategies on the study of immunomodulation of Mimosa pudica --- p.13 / Chapter 1.4 --- Toxicology / Chapter 1.4.1 --- Principles of the toxicological assays / Chapter 1.4.1.1 --- LD50 --- p.17 / Chapter 1.4.1.2 --- Enzyme assays --- p.18 / Chapter 1.4.1.3 --- Subacute toxicity test --- p.24 / Chapter 1.4.1.4 --- Reproductive toxicity test --- p.25 / Chapter Chapter Two: --- Materials and methods / Chapter 2.1 --- Materials / Chapter 2.1.1 --- Mimosa pudica --- p.27 / Chapter 2.1.2 --- Animals --- p.27 / Chapter 2.1.3 --- Chemicals --- p.28 / Chapter 2.2 --- Methods / Chapter 2.2.1 --- Extraction of Mimosa pudica --- p.32 / Chapter 2.2.2 --- Assays for the immunomodulatory effects of Mimosa pudica / Chapter 2.2.2.1 --- Cell preparation / Chapter a) --- Splenocytes --- p.35 / Chapter b) --- Thymocytes --- p.35 / Chapter c) --- Macrophages --- p.36 / Chapter 2.2.2.2 --- Splenocyte proliferation --- p.37 / Chapter 2.2.2.3 --- Thymocyte proliferation --- p.38 / Chapter 2.2.2.4 --- Phagocytic activity of macrophages --- p.39 / Chapter 2.2.2.5 --- Release of IL-1 by macrophages --- p.40 / Chapter 2.2.2.6 --- Plaque forming cells --- p.41 / Chapter 2.2.2.7 --- Restoration on splenocyte blastogenesis of old mice --- p.42 / Chapter 2.2.3 --- Assays for the toxicity of Mimosa pudica / Chapter 2.2.3.1 --- LD50 --- p.43 / Chapter 2.2.3.2 --- Enzyme assays --- p.43 / Chapter 2.2.3.3 --- Subacute toxicity --- p.43 / Chapter 2.2.3.4 --- Reproductive toxicity --- p.44 / Chapter 2.2.4 --- Statistical analysis --- p.44 / Chapter Chapter Three: --- Results / Chapter 3.1 --- Immunomodulatory effects of Mimosa pudica / Chapter 3.1.1 --- In vitro study on the lymphocyte proliferation / Chapter 3.1.1.1 --- Splenocyte proliferation --- p.45 / Chapter 3.1.1.2 --- Thymocyte proliferation --- p.50 / Chapter 3.1.2 --- In vivo study on the lymphocyte proliferation --- p.53 / Chapter 3.1.3 --- Phagocytic activity of macrophages --- p.58 / Chapter 3.1.4 --- Release of IL-1 by macrophages --- p.64 / Chapter 3.1.5 --- Plaque forming cells --- p.67 / Chapter 3.1.6 --- Restoration on splenocyte blastogenesis of old mice --- p.69 / Chapter 3.2 --- Toxicity of Mimosa pudica / Chapter 3.2.1 --- LD50 --- p.72 / Chapter 3.2.2 --- Enzyme assays --- p.75 / Chapter 3.2.3 --- Subacute toxicity --- p.80 / Chapter 3.2.4 --- Reproductive toxicity --- p.85 / Chapter Chapter Four: --- General discussion on the immunomodulatory effects and toxicity of Mimosa pudica / Chapter 4.1 --- Immunomodulatory effects of Mimosa pudica --- p.88 / Chapter 4.2 --- Toxicity of Mimosa pudica --- p.95 / Chapter Chapter Five: --- Concluding remarks --- p.99 / References --- p.104 / Appendix --- p.113

Siu, Hon Kei. / "November 2011." / Thesis (M.Phil.)--Chinese University of Hong Kong, 2012. / Includes bibliographical references (leaves 80-88). / Abstracts in English and Chinese; appendix in Chinese. / Thesis/Assessment Committee --- p.1 / Abstract --- p.2 / Content --- p.5 / Acknowledgements --- p.7 / Introduction --- p.8 / Background --- p.12 / Defining continuity of care --- p.12 / Measuring continuity of care --- p.14 / Effects of continuity of care --- p.15 / Factors affecting the continuity of care --- p.16 / Health care system in Hong Kong --- p.18 / Health care service charges in public and private sectors in Hong Kong --- p.19 / Primary care service in public and private sector --- p.21 / Health status and health seeking behaviours of Hong Kong people --- p.22 / Summary --- p.22 / Objectives --- p.24 / Methods --- p.25 / Target population --- p.25 / Sample size --- p.25 / Data collection --- p.26 / Preparation of questionnaire --- p.26 / Questionnaire in detail --- p.27 / Ethics issue --- p.32 / Statistical analysis --- p.32 / Results --- p.38 / Survey findings --- p.38 / Detailed analysis - respondents claimed that they needed a family doctor --- p.44 / Detailed analysis - respondents claimed that they had a family doctor --- p.46 / Discussion --- p.50 / Limitations of the study --- p.50 / Strengths of the study --- p.51 / Discussion of the findings --- p.52 / Implications --- p.59 / Conclusion --- p.62 / Tables and figures --- p.64 / Appendix --- p.75 / Bibliography --- p.80